All In Biotech

Drug Trial Radar · NCT04768686

FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer

A Phase 2 Study to Assess the Safety, Efficacy of FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer

Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

May 18, 2021

Primary completion

Aug 12, 2024

Study completion Aug 12, 2024

Sponsor

Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Feb 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is a Phase 2, open-label study to assess the efficacy, safety profile of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer. This study is designed to assess the potential anti-tumor activity when administered at the 100mg QD of FLX475 with pembrolizumab and will be conducted (2) cohorts as detailed below. * Cohort 1: EBV negative / CPI naïve gastric cancer subjects who have progressed on at least 2 prior systemic treatments for advanced or metastatic gastric cancer * Cohort 2: EBV positive / CPI naïve gastric cancer subjects who had at least 1 prior systemic treatment for advanced or metastatic gastric cancer Approximately 90 subjects may be enrolled across two cohorts to examine the safety and efficacy.

Conditions

  • Gastric Cancer

Interventions

  • FLX475Drug

    tablet

  • PembrolizumabDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) in Subjects Treated With FLX475 in Combination With PembrolizumabTime frame: Initial assessment performed after the first 2 cycles, then every 2 cycles for the first year, followed by every 3 cycles thereafter for up to 2 years and at any time per investigator's discretion and at ED/EOT, up to 2 years.

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

  • Gangnam Severance Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Hanllym University Medical Center

    Anyang-si, Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • The Catholic University of Korea St. Vincent Hospital

    Suwon, Gyeonggi-do, South Korea

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeollanam-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.